- Iris melanoma, a rare form of ocular melanoma originating in the iris, requires specialized treatment approaches to preserve vision and prevent metastasis. The escalating demand for iris melanoma treatment is primarily fueled by improved diagnostic capabilities leading to earlier detection, increased patient awareness about ocular health, and a growing preference for advanced, vision-sparing treatment options.
- North America dominates the iris melanoma treatment market with the largest revenue share of 47.01% in 2025, characterized by early adoption of advanced therapies, high healthcare expenditure, and a strong presence of key industry players and specialized ophthalmic oncology centers.
- The U.S. is experiencing substantial growth in iris melanoma treatment , particularly in academic medical centers and highly specialized eye clinics, driven by innovations from both established pharmaceutical companies and biotech startups focusing on targeted therapies and personalized medicine for rare ocular cancers.
- Asia-Pacific is expected to be the fastest-growing region in the iris melanoma treatment market during the forecast period due to increasing healthcare infrastructure, rising awareness about eye health, and a growing number of specialized ophthalmology centers.
- The cisplatin segment dominates the largest market revenue share of 34.15% in 2025,owing to its established efficacy in targeting ocular tumors and its frequent use in combination regimens for aggressive iris melanoma cases
